Industry News — Clinical Updates
Iluvien Gains Commercial Availability in Germany
Alimera Sciences, Inc., (Atlanta, GA) has announced that Iluvien, the first sustained-release pharmaceutical product for the treatment of chronic diabetic macular edema, is now commercially available in Germany.
In addition, Albert J. Augustin, MD, professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany, has treated the world's first patient with the implant injection since it became commercially available. The patient, a 67-year-old man, was diagnosed with diabetes more than 20 years ago.
Iluvien has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain, and the United Kingdom. Alimera Sciences is still seeking approval in the US.
Posted May 7, 2013